Insider Purchases: Inside the Buy
Tag: insider buying
CEO, CFO, COO, and President, CooperVision, Are All Buying Shares of The Cooper Companies. Should You?
The CEO, CFO, COO, and President of CooperCompanies all just bought shares. Insiders, institutions, and even the company itself are betting on the stock. Value play or just another lens cleaner? 👓💸
Can LKQ Replace Bear Parts with Bull Run: Insiders Think So
Insiders are wrenching their way into LKQ stock, and institutions hold more shares than exist (!). With profits intact, dividends rolling, and valuation gauges flashing cheap, could this be the ultimate rebuild? Or is it just another jalopy on Wall Street’s lot? 🛠️📉➡️📈
It’s Not Just Team Work: Atlassian Insider Invests Too
Atlassian (TEAM) isn’t just about team work—it’s insider work too. With new insider buys, strong institutional backing, and double-digit revenue growth, is TEAM ready to rally, or will competition and valuation risks keep it swiping left?
BellRing Brands (BRBR): Insider Sips, Protein Shakes, and Market Jitters
BellRing Brands (BRBR), maker of Premier Protein and Dymatize, has insiders buying stock while institutions double down. Sales are up, but lawsuits, debt, and competition are shaking things up. Value play or value trap?
Can Olin Cock Its Stock? Insiders Say Yes (Lock, Load, and Maybe Profit)
Olin ($OLN) insiders are loading up on shares while institutions already own 94% of the float. Profits are weak, ammo is hot, and bleach is… bleach. Can this 132-year-old company cock its stock for a rebound?
Is Boeing Ready to Fly?
Boeing’s new director — ex-Vanguard CEO Tim Buckley — just bought nearly $500K of stock. With a $619B backlog and cash flow stabilizing, is this aerospace giant finally ready for liftoff… or more turbulence?
Amrize Will Rise, Insiders Undoubtedly Think
Amrize insiders are loading up on stock like it’s on sale at Home Depot. With infrastructure and housing tailwinds, it’s tempting — but watch out for valuation cracks.
Eastman Kodak (KODK): Insider Buys, Debt Drama & a Pivot to Pills?!
Eastman Kodak insiders are snapping up shares, with CEO Jim Continenza leading the charge. But Kodak’s finances are shaky, its debt heavy, and its pivot to pharmaceuticals uncertain. High risk, high reward — or just a faded picture?
Elite Buys Ely: Should You Buy Lilly’s Stock Too?
Eli Lilly insiders are opening their wallets after the company crushed Q2 2025 — revenue up 38%, EPS up 92%, and blockbuster drugs Zepbound and Mounjaro fueling a raised guidance. Institutions are all-in, the pipeline is buzzing, but the valuation is sky-high. Is LLY worth chasing at $639, or is patience the better prescription?
Centene (CNC): CEO Buys at $25, Earnings Bleed Red, and the Stock’s on Life Support — Bargain or Bust?
Centene (CNC) just got a shot in the arm from its CEO and a director buying nearly $740K worth of stock near decade lows. But with Q2 earnings bleeding red, rising Medicaid costs, and valuation sliced in half, is this a bargain-bin opportunity or just a patient in the ICU?